ImmunityBio, Inc. - 8-K Filing
ImmunityBio's ANKTIVA® plus BCG met primary endpoint in Cohort A of QUILT-2.005 trial for BCG-naïve NMIBC (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
ImmunityBio's ANKTIVA® plus BCG met primary endpoint in Cohort A of QUILT-2.005 trial for BCG-naïve NMIBC (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)